BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

481 related articles for article (PubMed ID: 23055153)

  • 1. CD34⁺/CD38⁻ acute myelogenous leukemia cells aberrantly express CD82 which regulates adhesion and survival of leukemia stem cells.
    Nishioka C; Ikezoe T; Furihata M; Yang J; Serada S; Naka T; Nobumoto A; Kataoka S; Tsuda M; Udaka K; Yokoyama A
    Int J Cancer; 2013 May; 132(9):2006-19. PubMed ID: 23055153
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD82 regulates STAT5/IL-10 and supports survival of acute myelogenous leukemia cells.
    Nishioka C; Ikezoe T; Yang J; Nobumoto A; Kataoka S; Tsuda M; Udaka K; Yokoyama A
    Int J Cancer; 2014 Jan; 134(1):55-64. PubMed ID: 23797738
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tetraspanin Family Member, CD82, Regulates Expression of EZH2 via Inactivation of p38 MAPK Signaling in Leukemia Cells.
    Nishioka C; Ikezoe T; Yang J; Yokoyama A
    PLoS One; 2015; 10(5):e0125017. PubMed ID: 25955299
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IL-1β inhibits self-renewal capacity of dormant CD34⁺/CD38⁻ acute myelogenous leukemia cells in vitro and in vivo.
    Yang J; Ikezoe T; Nishioka C; Nobumoto A; Yokoyama A
    Int J Cancer; 2013 Oct; 133(8):1967-81. PubMed ID: 23564444
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD34⁺/CD38⁻ acute myelogenous leukemia cells aberrantly express Aurora kinase A.
    Yang J; Ikezoe T; Nishioka C; Nobumoto A; Udaka K; Yokoyama A
    Int J Cancer; 2013 Dec; 133(11):2706-19. PubMed ID: 23686525
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Senescence effects of Angelica sinensis polysaccharides on human acute myelogenous leukemia stem and progenitor cells.
    Liu J; Xu CY; Cai SZ; Zhou Y; Li J; Jiang R; Wang YP
    Asian Pac J Cancer Prev; 2014 Jan; 14(11):6549-56. PubMed ID: 24377566
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MicroRNA-9 promotes proliferation of leukemia cells in adult CD34-positive acute myeloid leukemia with normal karyotype by downregulation of Hes1.
    Tian C; You MJ; Yu Y; Zhu L; Zheng G; Zhang Y
    Tumour Biol; 2016 Jun; 37(6):7461-71. PubMed ID: 26678889
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Live kinase B1 maintains CD34
    Wang H; Wang X; Xin N; Qi L; Liao A; Yang W; Liu Z; Zhao C
    Mol Cell Biochem; 2017 Oct; 434(1-2):25-32. PubMed ID: 28397012
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acquired expression of osteopontin selectively promotes enrichment of leukemia stem cells through AKT/mTOR/PTEN/β-catenin pathways in AML cells.
    Mohammadi S; Ghaffari SH; Shaiegan M; Zarif MN; Nikbakht M; Akbari Birgani S; Alimoghadam K; Ghavamzadeh A
    Life Sci; 2016 May; 152():190-8. PubMed ID: 27063991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD34+CD38+CD19+ as well as CD34+CD38-CD19+ cells are leukemia-initiating cells with self-renewal capacity in human B-precursor ALL.
    Kong Y; Yoshida S; Saito Y; Doi T; Nagatoshi Y; Fukata M; Saito N; Yang SM; Iwamoto C; Okamura J; Liu KY; Huang XJ; Lu DP; Shultz LD; Harada M; Ishikawa F
    Leukemia; 2008 Jun; 22(6):1207-13. PubMed ID: 18418410
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Delineation of target expression profiles in CD34+/CD38- and CD34+/CD38+ stem and progenitor cells in AML and CML.
    Herrmann H; Sadovnik I; Eisenwort G; Rülicke T; Blatt K; Herndlhofer S; Willmann M; Stefanzl G; Baumgartner S; Greiner G; Schulenburg A; Mueller N; Rabitsch W; Bilban M; Hoermann G; Streubel B; Vallera DA; Sperr WR; Valent P
    Blood Adv; 2020 Oct; 4(20):5118-5132. PubMed ID: 33085758
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ginsenoside Rg1 Inhibits Cell Proliferation and Induces Markers of Cell Senescence in CD34+CD38- Leukemia Stem Cells Derived from KG1α Acute Myeloid Leukemia Cells by Activating the Sirtuin 1 (SIRT1)/Tuberous Sclerosis Complex 2 (TSC2) Signaling Pathway.
    Tang YL; Zhang CG; Liu H; Zhou Y; Wang YP; Li Y; Han YJ; Wang CL
    Med Sci Monit; 2020 Feb; 26():e918207. PubMed ID: 32037392
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enrichment of N-Cadherin and Tie2-bearing CD34+/CD38-/CD123+ leukemic stem cells by chemotherapy-resistance.
    Zhi L; Wang M; Rao Q; Yu F; Mi Y; Wang J
    Cancer Lett; 2010 Oct; 296(1):65-73. PubMed ID: 20444543
    [TBL] [Abstract][Full Text] [Related]  

  • 14. STAT5A regulates DNMT3A in CD34(+)/CD38(-) AML cells.
    Takeuchi A; Nishioka C; Ikezoe T; Yang J; Yokoyama A
    Leuk Res; 2015 Aug; 39(8):897-905. PubMed ID: 26059451
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phenotyping and Target Expression Profiling of CD34
    Blatt K; Menzl I; Eisenwort G; Cerny-Reiterer S; Herrmann H; Herndlhofer S; Stefanzl G; Sadovnik I; Berger D; Keller A; Hauswirth A; Hoermann G; Willmann M; Rülicke T; Sill H; Sperr WR; Mannhalter C; Melo JV; Jäger U; Sexl V; Valent P
    Neoplasia; 2018 Jun; 20(6):632-642. PubMed ID: 29772458
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functional alterations of Lin-CD34+CD38+ cells in chronic myelomonocytic leukemia and on progression to acute leukemia.
    Sun Q; So CC; Yip SF; Wan TS; Ma SK; Chan LC
    Leuk Res; 2008 Sep; 32(9):1374-81. PubMed ID: 18372040
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MUC1 is a potential target for the treatment of acute myeloid leukemia stem cells.
    Stroopinsky D; Rosenblatt J; Ito K; Mills H; Yin L; Rajabi H; Vasir B; Kufe T; Luptakova K; Arnason J; Nardella C; Levine JD; Joyce RM; Galinsky I; Reiter Y; Stone RM; Pandolfi PP; Kufe D; Avigan D
    Cancer Res; 2013 Sep; 73(17):5569-79. PubMed ID: 23867470
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aberrant marker expression patterns on the CD34+CD38- stem cell compartment in acute myeloid leukemia allows to distinguish the malignant from the normal stem cell compartment both at diagnosis and in remission.
    van Rhenen A; Moshaver B; Kelder A; Feller N; Nieuwint AW; Zweegman S; Ossenkoppele GJ; Schuurhuis GJ
    Leukemia; 2007 Aug; 21(8):1700-7. PubMed ID: 17525725
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD45
    Heo SK; Noh EK; Ju LJ; Sung JY; Jeong YK; Cheon J; Koh SJ; Min YJ; Choi Y; Jo JC
    BMC Cancer; 2020 Apr; 20(1):285. PubMed ID: 32252668
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blockade of CD82 by a monoclonal antibody potentiates anti-leukemia effects of AraC in vivo.
    Nishioka C; Ikezoe T; Yokoyama A
    Cancer Med; 2015 Sep; 4(9):1426-31. PubMed ID: 26139471
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.